[go: up one dir, main page]

MX2011011618A - Agentes terapeuticos 713. - Google Patents

Agentes terapeuticos 713.

Info

Publication number
MX2011011618A
MX2011011618A MX2011011618A MX2011011618A MX2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A MX 2011011618 A MX2011011618 A MX 2011011618A
Authority
MX
Mexico
Prior art keywords
therapeutic agents
melanin
prophylaxis
compounds
formula
Prior art date
Application number
MX2011011618A
Other languages
English (en)
Inventor
Lars Anders Mikael Johansson
Robert Andrew Judkins
Lanna Li
Bjorn Christian Ingvar Lofberg
Joachim Persson
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of MX2011011618A publication Critical patent/MX2011011618A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

En la presente, se describen compuestos de fórmula I (ver fórmula (II)) en donde R1, R2, R3, R4, R5, A, X, Y son como se han descrito en la especificación, su uso en composiciones farmacéuticas y en métodos de tratamiento o profilaxis de una enfermedad o afección relacionada con la hormona concentradora de melanina.
MX2011011618A 2009-05-01 2010-04-29 Agentes terapeuticos 713. MX2011011618A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17463009P 2009-05-01 2009-05-01
PCT/GB2010/050698 WO2010125390A1 (en) 2009-05-01 2010-04-29 Therapeutic agents 713

Publications (1)

Publication Number Publication Date
MX2011011618A true MX2011011618A (es) 2011-11-18

Family

ID=42290768

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011011618A MX2011011618A (es) 2009-05-01 2010-04-29 Agentes terapeuticos 713.

Country Status (23)

Country Link
US (1) US8110566B2 (es)
EP (1) EP2424870B1 (es)
JP (1) JP5763052B2 (es)
KR (1) KR20120023044A (es)
CN (2) CN102459279B (es)
AR (1) AR076516A1 (es)
AU (1) AU2010243341B2 (es)
BR (1) BRPI1014387A2 (es)
CA (1) CA2759230A1 (es)
DK (1) DK2424870T3 (es)
ES (1) ES2562831T3 (es)
HR (1) HRP20160128T1 (es)
HU (1) HUE026856T2 (es)
MX (1) MX2011011618A (es)
PL (1) PL2424870T3 (es)
PT (1) PT2424870E (es)
RU (1) RU2526055C2 (es)
SA (1) SA110310332B1 (es)
SI (1) SI2424870T1 (es)
SM (1) SMT201600041B (es)
TW (1) TW201100433A (es)
UY (1) UY32593A (es)
WO (1) WO2010125390A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100029685A1 (en) * 2006-10-25 2010-02-04 Neurosearch A/S Oxadiazole and thiadiazole compounds and their use as nicotinic acetylcholine receptor modulators
ES2527466T3 (es) * 2010-07-06 2015-01-26 Astrazeneca Ab Agentes terapéuticos 976
UY34194A (es) * 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
HU230880B1 (hu) 2015-04-15 2018-11-29 Richter Gedeon Nyrt Indol származékok
KR102866499B1 (ko) 2019-03-15 2025-10-02 더 제너럴 하스피탈 코포레이션 Tead 전사인자의 신규한 소분자 저해제
US20230084144A1 (en) * 2020-01-10 2023-03-16 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
HUP2200222A1 (hu) 2022-06-17 2023-12-28 Richter Gedeon Nyrt MCHR1 antagonisták a Prader-Willi szindróma kezelésére

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2473468C (en) * 2002-02-01 2011-06-21 Novo Nordisk A/S Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
SE0202134D0 (sv) 2002-07-08 2002-07-08 Astrazeneca Ab Therapeutic agents
US7541477B2 (en) * 2002-07-30 2009-06-02 Banyu Pharmaceutical Co., Ltd. Antagonists to melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
EP1593667A4 (en) 2003-02-12 2009-03-04 Takeda Pharmaceutical Amine derivative
US20060293298A1 (en) * 2003-04-10 2006-12-28 Bamford Mark J Compounds
US20070185079A1 (en) 2004-01-07 2007-08-09 Astrazeneca Ab Therapeutic agents I
GB0400193D0 (en) 2004-01-07 2004-02-11 Astrazeneca Ab Therapeutic agents
US7241787B2 (en) * 2004-01-25 2007-07-10 Sanofi-Aventis Deutschland Gmbh Substituted N-cycloexylimidazolinones, process for their preparation and their use as medicaments
TW200538098A (en) 2004-03-22 2005-12-01 Astrazeneca Ab Therapeutic agents
EP1786790B1 (en) * 2004-07-26 2009-06-03 Eli Lilly And Company Oxazole derivatives as histamine h3 receptor agents, preparation and therapeutic uses
PL1805169T3 (pl) 2004-10-18 2009-05-29 Lilly Co Eli Inhibitory receptora histaminowego H3, ich wytwarzanie i zastosowania terapeutyczne
US7838543B2 (en) 2004-12-17 2010-11-23 Eli Lilly And Company MCH receptor antagonists
EP1831194A4 (en) 2004-12-21 2009-12-02 Astrazeneca Ab HETEROCYCLIC ANTAGONISTS OF MCHr1 AND THERAPEUTIC APPLICATIONS THEREOF
JP2006176443A (ja) 2004-12-22 2006-07-06 Shionogi & Co Ltd メラニン凝集ホルモン受容体アンタゴニスト
CA2610671A1 (en) * 2005-05-31 2006-12-07 Astrazeneca Ab Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
CN101400677A (zh) 2006-01-06 2009-04-01 阿斯利康(瑞典)有限公司 化合物
AU2007275301A1 (en) 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11-beta-HSD-1
JP2010501553A (ja) * 2006-08-18 2010-01-21 アストラゼネカ アクチボラグ Ｍｃｈｒ１アンタゴニストとしてのチエノピリミジン−４−オン誘導体およびチエノピリダジン−７−オン誘導体
ES2483866T3 (es) 2006-12-05 2014-08-08 Janssen Pharmaceutica Nv Derivados de diaza-espiro-piridinona sustituidos novedosos para uso en enfermedades mediadas por MCH-1
ES2392276T3 (es) 2006-12-14 2012-12-07 Eli Lilly & Company Derivados de 5-[4-(azetidin-3-iloxi)-fenil]-2-fenil-5H-tiazolo[5,4-c]piridin-4-ona y su uso como antagonistas del receptor de MCH
WO2008131103A2 (en) 2007-04-17 2008-10-30 Vertex Pharmaceuticals Incorporated Drug discovery methods for aurora kinase inhibitors
EP2190815B1 (en) 2007-08-22 2011-08-10 F. Hoffmann-La Roche AG Pyrrolidine aryl-ether as nk3 receptor antagonists
BRPI0818581A2 (pt) * 2007-10-17 2015-07-21 Sanofi Aventis Carboxamidas n-fenil-bipirrolidina substituídas e uso terapêutico das mesmas
US20110071129A1 (en) * 2008-06-19 2011-03-24 Makoto Ando Spirodiamine-diaryl ketoxime derivative

Also Published As

Publication number Publication date
BRPI1014387A2 (pt) 2017-06-06
CA2759230A1 (en) 2010-11-04
US8110566B2 (en) 2012-02-07
SI2424870T1 (sl) 2016-03-31
ES2562831T3 (es) 2016-03-08
CN103936751A (zh) 2014-07-23
PT2424870E (pt) 2016-03-17
CN102459279B (zh) 2014-06-25
CN102459279A (zh) 2012-05-16
AU2010243341A1 (en) 2011-11-03
HUE026856T2 (en) 2016-07-28
JP2012525365A (ja) 2012-10-22
EP2424870B1 (en) 2015-12-16
US20100280000A1 (en) 2010-11-04
HRP20160128T1 (hr) 2016-02-26
SMT201600041B (it) 2016-02-25
EP2424870A1 (en) 2012-03-07
TW201100433A (en) 2011-01-01
AR076516A1 (es) 2011-06-15
RU2526055C2 (ru) 2014-08-20
PL2424870T3 (pl) 2016-05-31
KR20120023044A (ko) 2012-03-12
WO2010125390A1 (en) 2010-11-04
DK2424870T3 (en) 2016-02-15
UY32593A (es) 2010-11-30
SA110310332B1 (ar) 2013-12-10
JP5763052B2 (ja) 2015-08-12
AU2010243341B2 (en) 2014-02-13

Similar Documents

Publication Publication Date Title
MX2011011661A (es) Compuestos 1-cianoetilheterociclilcarboxamida sustituidos 750.
IN2012DN01233A (es)
PH12012500620A1 (en) Compounds
TW200738242A (en) Dihydropteridinones in the treatment of respiratory diseases
PH12012501122A1 (en) Pteridinones as inhibitors of polo-like kinase
GEP20146125B (en) Aminopyrimidines as syk inhibitors
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
UA115558C2 (uk) Алкілпіримідинові похідні для лікування вірусних інфекцій та подальших захворювань
MX2013003634A (es) Derivados policiclicos heterociclicos y metodos de uso de los mismos para el tratamiento de enfermedades virales.
EP2400847A4 (en) SPECIFIC DIARYLHYDANTOIN AND DIARYLTHIOHYDANTOINE COMPOUNDS
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2009003157A (es) Pirazoliltienopiridinas terapeuticas.
IN2012DN00971A (es)
IN2012DN00869A (es)
TN2011000172A1 (en) Therapeutic antiviral peptides
CL2008002689A1 (es) Compuestos derivados de heterociclo 1,4 piperidina sustituida; compuestos intermediarios; composicion farmaceutica; proceso de preparacion; y su uso en el tratamiento del alzheimer y esquizofrenia.
PL2150530T3 (pl) Podstawione pochodne sulfonamidu
EA201391486A1 (ru) Способы и композиции для лечения болезни паркинсона
MX2010009022A (es) Derivados 16 alfa, 17 alfa-acetal glucocorticoesteroideos y su uso.
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2011011618A (es) Agentes terapeuticos 713.
WO2010121164A3 (en) 1,4-benzodiazepinone compounds and their use in treating cancer
MX2010006108A (es) Inhibidores de estearoil-coa-desaturasa.
MY150931A (en) Substituted oxazolidinones and their use

Legal Events

Date Code Title Description
FG Grant or registration